Show simple item record

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

dc.contributor.authorBowyer, S
dc.contributor.authorPrithviraj, P
dc.contributor.authorLorigan, P
dc.contributor.authorLarkin, J
dc.contributor.authorMcArthur, G
dc.contributor.authorAtkinson, V
dc.contributor.authorMillward, M
dc.contributor.authorKhou, M
dc.contributor.authorDiem, S
dc.contributor.authorRamanujam, S
dc.contributor.authorKong, B
dc.contributor.authorLiniker, E
dc.contributor.authorGuminski, A
dc.contributor.authorParente, P
dc.contributor.authorAndrews, MC
dc.contributor.authorParakh, S
dc.contributor.authorCebon, J
dc.contributor.authorLong, GV
dc.contributor.authorCarlino, MS
dc.contributor.authorKlein, O
dc.date.accessioned2017-05-08T09:28:01Z
dc.date.issued2017-04
dc.identifier.citationBritish journal of cancer, 2017, 116 (8), pp. e15 - ?
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/636
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/bjc.2017.59
dc.formatPrint-Electronic
dc.format.extente15 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectMelanoma
dc.subjectSkin Neoplasms
dc.subjectCTLA-4 Antigen
dc.subjectProgrammed Cell Death 1 Receptor
dc.subjectIpilimumab
dc.titleReply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/bjc.2017.59
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
rioxxterms.licenseref.startdate2017-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue8
pubs.notes12 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume116
pubs.embargo.terms12 months
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail
Name:
JL_bjc201759a.pdf
Size:
122.2Kb
Format:
PDF
Description:
Published version
View/Open

This item appears in the following collection(s)

Show simple item record